Gilead's Quad non-inferior to Atripla

Gilead Sciences Inc. (NASDAQ:GILD) reported data on Wednesday from two Phase II trials to treat HIV. In one trial, the once-daily Quad regimen of elvitegravir, GS 9350 and Truvada emtricitabine/tenofovir met the primary endpoint of non-inferiority to Atripla emtricitabine/tenofovir/efavirenz in the proportion of patients with HIV RNA levels less than 50 copies/mL at 24 weeks.

Gilead said data from the second trial support GS 9350 as an effective boosting agent. Specifically, GS 9350-boosted Reyataz atazanavir plus Truvada had similar efficacy to Norvir ritonavir-boosted Reyataz plus Truvada. Full data from both trials will be presented at a scientific meeting this year. ...